 | ||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
| ||
Press Release Source: Viral Genetics, Inc. Viral Genetics to Present at Rodman & Renshaw Healthcare Conference and The PIPEs Conference Azusa, California; November 02, 2006 /PRNewswire-FirstCall/ -- Viral Genetics, Inc. (OTC Bulletin Board: VRAL) will present at the following two investment community conferences:
Rodman & Renshaw 8th Annual Healthcare Conference
The PIPEs Conference 2006 A live web cast of the Rodman & Renshaw presentation will be available in the Investors section of Viral Genetics' web site at www.viralgenetics.com. The web cast will be archived and accessible for 90 days. About Viral Genetics Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. Online at www.viralgenetics.com For additional information, please contact Kirsten Ayars at 805-452-7909. For investor inquiries, please contact Evan Pondel at 310-279-5973. This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition and the development of studies and strategies leading to commercialization of VGV-1 in the United States. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved. Source: Viral Genetics, Inc. Click here to return to our Press Release selection page.
|
|
|
|
Home | About Us | Our Team | Advisory Board | Discovery Our Vision | Immune-Based Therapies | TNP | Development | VGV-1 History | Product Timeline | Clinical Trials Press Releases | Media Kits | Media Inquiries | News Subscription Service Investor Contacts | Email Alerts | Contact Us | SEC Filings Glossary | Stock Information | Corporate Governance & Board of Directors University of Colorado License | Careers |
|
|
 |
|
|
